Clinical Trials Directory

Trials / Completed

CompletedNCT01209624

Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma

Prospective, Observational Study to Investigate the Long-term Effect of Xalatan® on Intraocular Pressure (IOP) and on Maintenance of Visual Field in Patients With Normal Tension Glaucoma (NTG)

Status
Completed
Phase
Study type
Observational
Enrollment
902 (actual)
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the long-term efficacy and safety of latanoprost monotherapy in patients with normal tension glaucoma (NTG) using a prospective, observational design. Visits were scheduled at 6-month intervals for 24 months. Intraocular pressure (IOP), optic nerve head findings, visual field status, and adverse events were recorded.

Conditions

Timeline

Start date
2006-08-01
Primary completion
2009-09-01
Completion
2009-09-01
First posted
2010-09-27
Last updated
2021-02-26
Results posted
2010-10-26

Source: ClinicalTrials.gov record NCT01209624. Inclusion in this directory is not an endorsement.

Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma (NCT01209624) · Clinical Trials Directory